HDAC1/2 Activators for Remyelination in Multiple Sclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for demyelinating diseases like Multiple Sclerosis primarily focus on reducing immune attacks but fail to directly promote or accelerate the regeneration of damaged myelin sheaths, leading to progressive neuronal loss as the disease progresses and regeneration capacity diminishes with age.
Innovation Solution
Development of HDAC1/2 activators, such as theophylline, to increase HDAC1 and HDAC2 activity and expression, which promotes myelination and remyelination in both the central and peripheral nervous systems, thereby treating and preventing demyelinating diseases by enhancing the regeneration of nerve cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for demyelinating diseases focus on reducing immune attacks, then immune-mediated damage is reduced, but regeneration of damaged myelin sheaths is not promoted and neuronal loss progresses
Solution Approach 1:
Instead of only inhibiting HDAC activity to prevent immune attacks, the invention applies HDAC activators to reverse the approach and directly promote myelin regeneration through epigenetic modulation of oligodendrocyte function and differentiation
Solution Approach 2:
The invention changes the parameter of HDAC enzyme activity from inhibited to activated state, using small molecules that increase HDAC1/2 activity to accelerate remyelination and promote oligodendrocyte maturation
2Productivity
If HDAC activity is increased to promote remyelination, then regeneration of nerve cells is accelerated, but the complexity of the treatment mechanism increases
Solution Approach 1:
The invention uses small molecule compounds as intermediaries that selectively activate HDAC1/2 enzymes, which then mediate the epigenetic changes required for oligodendrocyte differentiation and myelin production, simplifying the treatment approach while maintaining biological complexity
Data Source
AI summary
The present invention is based on the surprising finding of the property of promoting myelination of activators of histone deacetylase (HDAC) 1 and 2. In particular, such activators have the capacity of accelerating and increasing remyelination after lesions to the myelin of nerve cells of the peripheral and central nervous systems. The present inventor found that HDAC2 deacetylates eEF1A1 and thereby prevents the latter from removing outside the nucleus key inducers of myelin genes transcription. The HDAC1/2 activators are useful in the treatment of diseases associated with demyelination, such as Multiple Sclerosis.